Effect of Unani Formulation in Nazla.
- Conditions
- Health Condition 1: J309- Allergic rhinitis, unspecified
- Registration Number
- CTRI/2020/03/024252
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Symptoms persisted for more than 4 days per week or more than 4 weeks per year and at least one of the following rhinitis-associated conditions: nasal congestion, rhinorrhea, sneezing and nasal itching
2.Patients who will give consent and able to do follow up
1.Patients suffering from systemic illness like Hypertension, DM, Malignancy, Liver or Kidney dysfunction
2.Patients suffering from congenital nasal abnormalities like nasal dermoid cysts, congenital midline nasal masses, Deviated Nasal Septum, Atrophic rhinitis, Sinusitis, Hypertrophic turbinates, Adenoidal hypertrophy, Foreign bodies or Asthma
3.Patients below 18 and above 50 years
4.Patients with past history of nose surgery
5.Patients had received systematically administered corticosteroids, antihistamines, decongestants or CAM therapy within 02 weeks prior to enrolment
6.Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Changes in Total Nasal Symptom Score (TNSS) and <br/ ><br>2.Allergic Rhinitis Control Test (ARCT) <br/ ><br>Timepoint: 0th Day, 07th Day, 14th Day, 21st Day, 28th Day <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Improvement in Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini RQLQ) <br/ ><br>2. AEC <br/ ><br>Timepoint: 0th Day, 07th Day, 14th Day, 21st Day, 28th Day <br/ ><br>